Mirum's liver infection drug lowers virus levels in late-stage study

By Sneha S KMirum Pharmaceuticals NASDAQ:MIRM on Monday said its experimental hepatitis drug reduced levels of the virus in patients, meeting the main goal of a late-stage study.Here are some key details